Good morning, all. Damian here with a glimpse at the next big thing in Alzheimer’s disease, Pfizer’s future in treating obesity, and the downstream effects of a biotech slump.The need-to-know this morning• Merck reported third-quarter adjusted earnings of $2.13 per share, or 9% ahead of analyst consensus. Revenue in the quarter was $16 billion, led […]
